Compare NYXH & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NYXH | TNYA |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 168.2M |
| IPO Year | 2021 | 2021 |
| Metric | NYXH | TNYA |
|---|---|---|
| Price | $1.66 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $9.33 | $5.33 |
| AVG Volume (30 Days) | 118.5K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $213.98 | N/A |
| Revenue Next Year | $126.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $0.53 |
| 52 Week High | $6.87 | $2.35 |
| Indicator | NYXH | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 38.79 |
| Support Level | $1.28 | $0.65 |
| Resistance Level | $1.70 | $0.81 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 96.20 | 9.97 |
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.